Sezary syndrome: diagnosis and management

ABSTRACT We describe a case of a delayed diagnosis of Sezary syndrome in a patient with longstanding generalised pruritus, erythroderma, alopecia and nail dystrophy. We highlight some of the difficulties in diagnosis despite the fact that all patients have a characteristic circulating malignant T-cell lymphocyte in peripheral blood. These cells with cerebriform nuclei should be sought in peripheral blood films and further evaluated using flow cytometry in all patients with an erythrodermatous presentation. We summarise current treatment options although, as with all rare diseases, there are few randomised controlled clinical trials to inform decisions on optimal therapy for each individual patient.

KEYWORDS Sezary syndrome, Sezary cells, erythroderma, flow cytometry

INTRODUCTION

Sezary syndrome (SS) is a triad of erythroderma, generalised lymphadenopathy and the presence of clonally related neoplastic T-cells with cerebriform nuclei (Sezary cells) in skin, lymph nodes and peripheral blood. These cells can be easily overlooked in peripheral blood smears: the nuclear folding may only be apparent after careful examination at high power under immersion oil. In addition, one or more of the following criteria are required: an absolute Sezary cell count of at least 1x10^9/L, an expanded CD4 positive T-cell population resulting in a CD4/CD8 ratio greater than ten and/or loss of one or more T-cell antigens. It accounts for <5% of all cases of cutaneous T-cell lymphoma (CTCL). Sezary syndrome typically presents in adults over 60 years of age, with a male predominance. Initially the presentation with generalised itch and erythroderma may be non-specific. In up to one-third of skin biopsies (later confirmed as SS) the histologic picture may be non-specific, making diagnosis difficult and consequently delayed. In more advanced cases there may be alopecia, ectropion, onychodystrophy and palmar/plantar hyperkeratosis. Lymph nodes commonly show dermatopathic changes, however a monotonous infiltrate of Sezary cells with loss of normal architecture is typical of nodal involvement. The bone marrow is often not involved but may show a light, predominantly interstitial, infiltrate.

CASE REPORT

A 72-year-old female presented to Dermatology with a diffuse itchy erythroderma affecting her face, trunk, legs and palms. This was extensively investigated but no clear cause was identified. The full blood count was normal and a skin biopsy was in keeping with a chronic dermatitic process. The biopsy was reviewed specifically by a lymphoma pathologist and no overt features of CTCL were present. She was treated with topical steroids and antihistamines.

Over the subsequent two years her symptoms worsened with intense itch, peeling of the skin of her palms and soles, marked dystrophy of her nails (hands and feet) and extensive, patchy alopecia. She did not have type B symptoms of lymphoma.

Examination revealed generalised mild erythroderma with loose, thickened skin, marked peeling of her palms and soles and nail dystrophy. There was patchy alopecia, loss of eyelashes and mild bilateral ectropion (Figure 1). A 2 cm right axillary node and 1 cm left groin node were palpable. She had a peripheral blood lymphocytosis of 8x10^9/L with a population of atypical lymphocytes with convoluted nuclei (Figure 2A). Flow cytometry showed an abnormal CD3 positive, CD4 positive T-cell population showing partial loss and weak expression of CD7, but absent CD25, with an absolute count of 3x10^9/L. Further skin biopsy showed a prominent epidermotropic CD4 positive T-cell infiltrate involving the lower third of the epidermis (Figure 2B). A computed tomography (CT) scan showed bilateral axillary and bilateral inguinal lymphadenopathy only and bone marrow trephine showed no evidence of infiltration. An axillary node biopsy showed florid dermatopathic changes in addition to early involvement with CTCL. The same monoclonal T-cell receptor gene rearrangement was identified by polymerase chain reaction (PCR) in peripheral blood, skin biopsy and lymph node biopsy, confirming a diagnosis of Sezary syndrome (Figure 3).
Sezary syndrome is an aggressive, incurable disorder with a 10–20% five-year overall survival rate. The European Organisation for Research and Treatment of Cancer (EORTC) have produced guidelines for the management of CTCL. First-line recommendations for treatment of SS are extracorporeal photopheresis (ECP), interferon alpha +/- psoralen combined with ultraviolet A (PUVA), low-dose chlorambucil with prednisolone and denileukin diftitox (an IL2-diptheroid toxin fusion protein). There are few phase III randomised studies to assist decisions on optimal first-line therapy. Most published evidence comes from small case series and expert opinion. Treatment is aimed at symptom control, with partial Sezary cell clearance being the norm. Complete clinical responses to treatment are unusual.

**DISCUSSION**

**FIGURES 1A** Loose, thickened skin; **B** nail dystrophy; **C** loss of eyelashes and bilateral ectropion; **D** patchy alopecia.
The use of ECP will achieve a response in 55–70% of patients: responders tend to have a higher baseline lymphocyte count and proportion of Sezary cells. Extracorporeal photopheresis is currently only available through six centres in the UK. A typical regimen might consist of treatment on two consecutive days every two weeks for the first three months and then monthly for the following nine months, according to clinical response. Cells undergo leukapheresis and then photoactivation with 8-methoxypsoralen (8-MOP) in combination with UVA. The 8-MOP binds covalently to DNA in the separated leucocytes resulting in cell cycle arrest and apoptosis. Once re-infused, the apoptotic leucocytes are phagocytosed by antigen-presenting cells. This results in production of specific tumour suppressor cells which go on to target malignant lymphocytes.

Chlorambucil and prednisolone therapy is one of the longer established regimes for this condition. It has been shown to prolong survival by a median of 3.2 years, from the onset of erythroderma, when compared to a variety of other combination chemotherapy and irradiation regimens. A low dose of chlorambucil, typically 4 mg daily, is given continuously with prednisolone in tapering doses according to response.

Interferon alpha therapy can achieve meaningful responses in up to 64% of CTCL patients, with time to progression of 4 to 27 months, when used in escalating doses from 3 MU daily for a maximum of ten weeks. Dose-related side-effects of malaise, depression, anorexia and weight loss, however, were common. Denileukin difitox has been studied in CD25 positive CTCL cases with an overall response in 30% of patients. The majority of SS cases, however, are CD25 negative. Second-line treatments have been assessed only in very small studies. Methotrexate given weekly at a dose of 5–25 mg has been reported to achieve a response in 13 out of 17 cases. A further small study looking at the efficacy of bexarotene achieved a response rate of 24%. Alemtuzumab therapy can achieve initial responses but many cases show early disease progression. Combination chemotherapy regimens (etoposide, prednisolone, vincristine, cyclophosphamide and daunorubicin [EPOCH], fludarabine/cyclophosphamide, and cyclophosphamide, vincristine,prednisone [CVP]) have been used in refractory CTCL but the experience in treating SS is extremely limited. Despite reported responses of up to 80%, many of these regimes are toxic and immunosuppressive and will not be tolerated by many patients. In well-selected young patients with a suitable sibling donor, reduced-intensity conditioning allogeneic transplantation should be considered and an estimated three-year survival of 54% has been reported. Importantly, many patients with SS die of opportunistic infection as a result of progressive depletion of normal CD4 positive T-cells through the effects of the disease and its treatment.

We chose to commence therapy with prednisolone 20 mg daily for the first few weeks prior to the introduction of more definitive therapy with ECP. She had an excellent early response with rapid improvement of the pruritus, allowing uninterrupted sleep, with a lessening of the peeling and fissuring of the palms and soles. The patient also showed a good early response to ECP. She has received six photopheresis treatments to date and there has been a significant improvement in the erythroderma.

**FIGURE 2A** Sezary cells in peripheral blood: atypical lymphocytes with convoluted nuclei.

**FIGURE 2B** CD4 positive T-cell infiltrate involving the lower third of the epidermis (skin biopsy, H&E stain, x400 magnification).
Sezary syndrome is a rare disease characterised by the triad of erythroderma, generalised lymphadenopathy and the presence of clonally related neoplastic T-cells with cerebriform nuclei (Sezary cells) in skin, lymph nodes and peripheral blood.

All patients presenting with unexplained erythroderma should have a peripheral blood film scrutinised for the typical lymphoid cells with cerebriform nuclei and flow cytometry for the detection of a CD4 positive population lacking one or more T-cell antigens. Typical Sezary cells are CD3 positive, CD4 positive with loss or weak expression of CD7 and CD26.\(^{14}\)

Sezary syndrome incurs significant morbidity causing intractable pruritus, skin damage, nail dystrophy and alopecia and a poor prognosis, with a median survival of two to four years. Although treatment guidelines exist, there is still uncertainty with respect to the optimal initial therapy for patients.
REFERENCES


